Inderal La

Thyroid Crisis, Atrial Fibrillation, Migraine + 23 more

Treatment

5 FDA approvals

20 Active Studies for Inderal La

What is Inderal La

Propranolol

The Generic name of this drug

Treatment Summary

Propranolol is a medication used to treat high blood pressure. It is a combination of two enantiomers, with the S(-)-enantiomer having 100 times the binding affinity for beta adrenergic receptors. Propranolol has been approved by the FDA since 1967 and is used to treat a number of other conditions.

Inderal

is the brand name

image of different drug pills on a surface

Inderal La Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Inderal

Propranolol

1967

471

Approved as Treatment by the FDA

Propranolol, also known as Inderal, is approved by the FDA for 5 uses including Obstructive Hypertrophic Cardiomyopathy and Tremor, Essential .

Obstructive Hypertrophic Cardiomyopathy

Tremor, Essential

Helps manage Tremor, Essential

Essential Tremor

Helps manage Tremor, Essential

Cardiomyopathy, Hypertrophic

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Hydrochlorothiazide

Effectiveness

How Inderal La Affects Patients

Propranolol is a drug used to treat high blood pressure. It can be taken in one or two doses each day and its effects last long. If someone stops taking propranolol suddenly, they may experience chest pain or heart attacks.

How Inderal La works in the body

Propranolol blocks certain receptors in the body, resulting in decreased blood vessel growth and increased cell death. It also reduces the levels of hormones that regulate blood pressure.

When to interrupt dosage

The measure of Inderal La is contingent upon the identified affliction, including Catecholamines, Hypertensive illness and Hemangiomas. The amount of dosage is contingent upon the method of delivery (e.g. Solution - Oral or Capsule, extended release - Oral) as specified in the table below.

Condition

Dosage

Administration

Adrenergic Alpha-Antagonists

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Heart Attack

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Tachyarrhythmia caused by Digitalis intoxication

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Psychomotor Agitation

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Tremor

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Thyrotoxicosis

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Chest Pain

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Supraventricular Arrhythmias

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Hemangioma

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Cardiomyopathy, Hypertrophic

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Proliferating Infantile Hemangioma

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Hypertensive disease

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Performance Anxiety

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Pheochromocytoma

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Ventricular Tachycardia

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Migraine

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Gastroesophageal variceal hemorrhage prophylaxis

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Catecholamines

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Migraine Disorders

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Atrial Fibrillation

, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL

, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Warnings

Inderal La has fifteen contraindications and should not be adopted when confronting the conditions presented in the following table.

Inderal La Contraindications

Condition

Risk Level

Notes

Heart Decompensation

Do Not Combine

Bronchial Spasm

Do Not Combine

Asthma

Do Not Combine

Infants Weighing <2kg

Do Not Combine

Low Blood Pressure

Do Not Combine

Sick Sinus Syndrome

Do Not Combine

Asthma

Do Not Combine

Pheochromocytoma

Do Not Combine

Atrioventricular Block

Do Not Combine

Slow Heart Rate

Do Not Combine

Shock, Cardiogenic

Do Not Combine

Heart Decompensation

Do Not Combine

Prematurity

Do Not Combine

Sinus Bradycardia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Propranolol may interact with Pulse Frequency

There are 20 known major drug interactions with Inderal La.

Common Inderal La Drug Interactions

Drug Name

Risk Level

Description

4-Bromo-2,5-dimethoxyphenethylamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Propranolol.

4-Methoxyamphetamine

Major

The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Propranolol.

Abediterol

Major

Propranolol may decrease the bronchodilatory activities of Abediterol.

Adrafinil

Major

The therapeutic efficacy of Adrafinil can be decreased when used in combination with Propranolol.

Agrostis gigantea pollen

Major

The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Propranolol.

Inderal La Toxicity & Overdose Risk

Signs of an overdose of propranolol include low blood pressure, seizures due to low blood sugar, restlessness, and difficulty sleeping. People with asthma may have difficulty breathing. To treat an overdose, medical professionals will monitor vital signs and mental status, and administer fluids to raise blood pressure, atropine to slow an irregular heartbeat, and drugs to open up the airways. If the patient does not respond to fluids, they may be given glucagon followed by drugs that increase the activity of certain hormones. Dialysis usually cannot remove propranolol from the body because it binds strongly to proteins.

image of a doctor in a lab doing drug, clinical research

Inderal La Novel Uses: Which Conditions Have a Clinical Trial Featuring Inderal La?

249 active studies are currently assessing the potential of Inderal La in providing relief from Migraine, Catecholamine-induced disorders and Hypertensive diseases.

Condition

Clinical Trials

Trial Phases

Atrial Fibrillation

94 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1

Heart Attack

23 Actively Recruiting

Not Applicable, Phase 1, Phase 4, Phase 2, Early Phase 1, Phase 3

Coronary Artery Disease

1 Actively Recruiting

Not Applicable

Chest Pain

2 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Adrenergic Alpha-Antagonists

0 Actively Recruiting

Migraine

51 Actively Recruiting

Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1

Hemangioma

0 Actively Recruiting

Gastroesophageal variceal hemorrhage prophylaxis

0 Actively Recruiting

Migraine Disorders

1 Actively Recruiting

Phase 3

Catecholamines

0 Actively Recruiting

Thyroid Crisis

0 Actively Recruiting

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Pheochromocytoma

0 Actively Recruiting

Thyrotoxicosis

0 Actively Recruiting

Cardiovascular Mortality

0 Actively Recruiting

Myocardial Infarction

0 Actively Recruiting

Tremor

0 Actively Recruiting

Cardiomyopathy, Hypertrophic

0 Actively Recruiting

Proliferating Infantile Hemangioma

0 Actively Recruiting

Psychomotor Agitation

0 Actively Recruiting

Inderal La Reviews: What are patients saying about Inderal La?

5

Patient Review

8/26/2013

Inderal La for Essential Tremor

I've been using Inderal LA for over two decades to manage a head tremor. It's been incredibly effective, but can sometimes be tough to coordinate with my asthma medication.

5

Patient Review

10/7/2014

Inderal La for Migraine Prevention

This medication has been great for me. I used to get two migraines a month, but since starting this treatment, I haven't had any at all.

4.7

Patient Review

10/19/2009

Inderal La for Migraine Prevention

I was prescribed this medication about 9 years ago for a rapid heartbeat. It worked for several years then had to increase the dose because symptoms returned. Unfortunately, I also experienced EXTREME HAIR LOSS - which is apparently a common side effect of beta blockers (according to my research).

4.7

Patient Review

5/15/2011

Inderal La for Migraine Prevention

Since starting this medication a few weeks ago, my migraines have greatly improved. Although I do feel tired the day after taking it.

4.7

Patient Review

3/16/2010

Inderal La for High Blood Pressure

This treatment is great! It really helped me and I'm grateful for it.

4.7

Patient Review

9/27/2009

Inderal La for Migraine Prevention

4.3

Patient Review

7/22/2015

Inderal La for Migraine Prevention

The drug has been helpful in managing my migraines, though I haven't seen a total prevention of them. The most difficult side effect is an uncontrollable hunger; however, I've found that drinking water and chewing gum helps to alleviate this issue somewhat.

4.3

Patient Review

8/3/2013

Inderal La for Ventricular Rate Control in Atrial Fibrillation

This medication caused an irregular heart beat for me.

4

Patient Review

4/30/2011

Inderal La for Essential Tremor

I've been using these Inderal tablets for over 15 years to help with my hand tremor. They work well, but I have noticed that if I take them too regularly, they become less effective. I haven't increased the 40mg dose per day because I read on this site that it shouldn't be taken by patients with low blood sugar (which is my case). If anyone could provide clarification on this from a medical standpoint, I would appreciate it.

4

Patient Review

11/21/2011

Inderal La for High Blood Pressure

This medication was easy to take and had minimal side effects. My blood pressure lowered significantly, and it also took care of my minor tremors.

3.7

Patient Review

1/28/2014

Inderal La for Migraine Prevention

Though this drug is very effective in preventing migraines, the constant tiredness it causes is difficult to manage. I also have trouble working out; if I take the medication before going to the gym, I become nauseous, sweaty and dizzy. Because of these side effects, I stopped taking the drug a couple years ago. However, since my migraines have returned (I average 5 per month), I am reconsidering. Taking magnesium/B2 for several months does not seem to be an effective alternative to prescription drugs.

3

Patient Review

3/15/2010

Inderal La for Osteoporosis

I was recently prescribed Inderal LA 60 mg to take once a day for tremors in my hands that may be caused by taking Zoloft. I have been on the medication for about a month now and I still have shaky hands. I am seeing my doctor soon to find out what is going on, but as of right now, it does not seem like this drug is effective for treating tremors. Has anyone else had a similar experience using this drug?

2.3

Patient Review

7/7/2012

Inderal La for Essential Tremor

The tremors have not gone away and they are still affecting my daily life.

1.3

Patient Review

11/4/2011

Inderal La for High Blood Pressure

I experienced some serious side effects after taking this drug for a few years. My blood pressure went down, but I developed impotence and insomnia that didn't go away even after I stopped taking the drug. In 2009, I also developed Peyronie's disease. It's worrying that all of these conditions are rare side effects of this medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about inderal la

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does Inderal LA treat?

"INDICATIONS:

Propranolol HCl is indicated for the treatment of high blood pressure, angina pectoris, and hypertrophic subaortic stenosis. It is also indicated for the prevention of migraine headaches."

Answered by AI

Is propranolol ER the same as Inderal LA?

"HCL

Propanolol HCL ER is used to lower blood pressure and heart rate, making it easier for the heart to pump blood to the rest of the body. It can also be used to prevent migraine headaches. Propanolol HCL ER works by relaxing the blood vessels in the brain that cause migraines."

Answered by AI

What is difference between Inderal and Inderal LA?

"There was no significant difference in blood pressure levels between conventional propranolol and 'Inderal' LA, but the mean peak blood level of propranolol was lower with 'Inderal' LA and occurred later."

Answered by AI

What is Inderal LA 60 mg used for?

"This medication is a beta blocker that is used to treat high blood pressure, irregular heartbeats, shaking (tremors), and other conditions as determined by your doctor. It is used after a heart attack to improve survival rates. It is also effective in preventing migraine headaches and chest pain (angina)."

Answered by AI

Clinical Trials for Inderal La

Image of Hāmākua-Kohala Health Center in Honokaa, United States.

Produce Prescription for High Blood Pressure

18+
All Sexes
Honokaa, HI

This multi-site randomized controlled trial uses a community-based approach to evaluate a Food as Medicine program for Native Hawaiian and Pacific Islander (NHPI) adults in Hawaii who have high blood pressure and difficulty affording healthy food. The study has two main goals: (1) to implement a produce prescription program and see if adding personal support from Community Health Workers (CHW) improves blood pressure among other health outcomes, and (2) to determine the program's cost-effectiveness. The study will take place across three Federally Qualified Health Centers in Hawaii. Produce prescription program participants at each site will receive $100 per month, either in the form of produce boxes or monthly vouchers to purchase fruits and vegetables, for 12 months (totaling $1200). In past studies, personal challenges (e.g., lack of transportation, lack of cooking skills) have made it difficult for participants to use the vouchers and/or the purchased produce. In other food as medicine interventions, participants have similarly faced various personal, social, and environmental barriers that limit the program's efficacy. To help participants navigate through these challenges, the investigators want to test adding 1-on-1 support from a CHW throughout the program. Other studies have found that health interventions delivered by CHWs have been effective in reducing blood pressure, blood glucose and weight, especially among vulnerable populations, such as NHPIs and those with food insecurity. The CHWs in this study will receive a training using a curriculum tailored specifically to their community and that is in alignment with the Pilinahā: The Four Connections Framework, which focuses on key connections that Indigenous people seek to attain health and can be employed to overcome health disparities. To test the effectiveness of the added CHW support, there will be two groups of participants: Group 1 (Intervention) will receive the monthly produce prescription ($100 vouchers or produce box) plus meet with a CHW every two months for support with program challenges. Group 2 (Control) will receive the same monthly produce prescription, but will not have meetings with a CHW. The investigators want to see if the added support from CHWs leads to better blood pressure results, among other health outcomes. Upon providing informed consent and enrolling into the program, produce prescription program participants will: * Attend 5 study visits over the one year program. These happen at the start, and then at 3, 6, 9, and 12 months. * Complete health checks at the first visit. This includes getting a home blood pressure monitor and learning about heart health and nutrition. Staff will measure height, weight, waist size, and blood pressure. * Answer surveys about their demographic background, health habits, diet, and culture. * Receive $100 in vouchers every month for 12 months to redeem for fruits and vegetables at a local retailer. * Group 1 will additionally meet with a CHW every two months for 1-on-1 support with any challenges related to the program. * Group 2 will receive monthly reminders to use their vouchers but no CHW meetings. After the program ends, researchers will analyze the financial value of the intervention. This involves calculating the total cost to run the program (including vouchers, CHW training and salaries, and administrative costs) and comparing it to potential savings in healthcare costs. By looking at improvements in blood pressure, researchers can estimate how many heart-related health problems were prevented and how much money was saved on medical care.

Waitlist Available
Has No Placebo

Hāmākua-Kohala Health Center (+2 Sites)

Image of Columbia University Irving Medical Center in New York, United States.

Telehealth vs Traditional Rehab for Heart Attack

18+
All Sexes
New York, NY

Cardiac rehabilitation (CR) is an effective evidence-based intervention that improves outcomes in patients with acute coronary syndrome (ACS), but many eligible patients do not complete the program. A hybrid CR intervention that combines telehealth, home-based, and clinic-based components (TeleheartCR) may increase participation by addressing barriers to access while maintaining the functional capacity benefits of traditional CR. The purpose of this study is to conduct a randomized controlled trial comparing TeleheartCR with traditional clinic-based CR in patients with ACS to evaluate differences in program adherence and pre-to-post program change in functional capacity.

Recruiting
Has No Placebo

Columbia University Irving Medical Center

Andrea T. Duran, PhD

Image of Tucson Medical Center in Tucson, United States.

VARIPULSE Catheter for Atrial Fibrillation

18 - 80
All Sexes
Tucson, AZ

The purpose of this study is to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and superior vena cava (heart veins; PVI and SVCI), with or without another technique called posterior wall isolation (PWI). Also, to assess how safe it is for participants who are having a catheter ablation procedure and at the same time receiving another procedure called left atrial appendage occlusion (LAAO; to reduce stroke risk). Additionally, to assess how well VARIPULSE catheter system works over a long period of time for treatment of PsAF in participants undergoing catheter ablation.

Waitlist Available
Has No Placebo

Tucson Medical Center (+2 Sites)

Biosense Webster, Inc. Clinical Trial

Biosense Webster, Inc.

Have you considered Inderal La clinical trials?

We made a collection of clinical trials featuring Inderal La, we think they might fit your search criteria.
Go to Trials
Image of Mass General Brigham in Boston, United States.

Single-lead ECG Screening for Atrial Fibrillation

18 - 90
All Sexes
Boston, MA

The goal of this prospective, non-randomized pilot study is to learn whether predictions from a previously validated 12-lead ECG-based artificial intelligence (AI) algorithm (ECG-AI) identify people more likely to have undiagnosed atrial fibrillation (AF). The main questions it aims to answer are: Do people predicted to have high risk of AF using ECG-AI have a higher rate of new AF diagnosis using 1L ECG screening compared with people predicted to have a low risk? Do AI-based AF risk estimates from the 12-lead ECG correlate with AF risk estimates from the 1L ECG? Do people find 1L ECG screening for AF acceptable and useful? Participants will: Undergo screening with 1L ECG mailed to their home Complete a survey assessing attitudes toward 1L ECG screening Complete a 14-day patch monitor on 1 or 2 occasions depending on 1L ECG results

Waitlist Available
Has No Placebo

Mass General Brigham

Have you considered Inderal La clinical trials?

We made a collection of clinical trials featuring Inderal La, we think they might fit your search criteria.
Go to Trials
Image of Children's Mercy in Kansas City, United States.

Virtual Reality Neurofeedback for Migraine

10 - 16
All Sexes
Kansas City, MO

The goal of this clinical trial is to learn whether a home-based virtual reality (VR) neurofeedback program is feasible and acceptable for adolescents with migraine. The study will also explore whether the program may improve headache-related outcomes. The main questions it aims to answer are: Is it feasible to enroll, randomize, and retain adolescents with migraine in this study? Do participants complete the VR sessions and study procedures as intended? Are there preliminary signals that the VR neurofeedback program may improve headache-related disability and symptoms? Researchers will compare Immersive Neurofeedback Self-Regulation Training (INSeRT), which uses brain activity recorded from a wearable electroencephalogram (EEG) headband to guide the VR experience, to a comparison VR program that presents immersive imagery without neurofeedback or guided relaxation training. Participants will: Complete a 4-week baseline period that includes headache logs, questionnaires, and a laboratory EEG assessment Be randomly assigned to one of two VR programs Complete VR sessions at home three times per week for 4 weeks Complete questionnaires at the end of treatment and again approximately 3 months later Repeat the laboratory EEG assessment at the end of treatment

Recruiting
Has No Placebo

Children's Mercy

Mark A Connelly, PhD

Image of SEC Clinical Research in Dothan, United States.

REGN7508 + REGN9933 for Atrial Fibrillation

18+
All Sexes
Dothan, AL

This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. When this happens, blood cannot move smoothly through the heart; it can slow down or pool in one spot, which can lead to the formation of blood clots. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how effective and safe REGN7508 and REGN9933, individually, are in preventing ischemic stroke or systemic embolism in people with atrial fibrillation who cannot or may choose to not take blood thinners. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well does REGN7508 or REGN9933 lower the risk of having an ischemic stroke and/or systemic embolism compared to the placebo * How well does REGN7508 or REGN9933 lower the risk of having a major health problem affecting heart and blood circulation compared to placebo * How well does REGN7508 or REGN9933 lower the risk of death compared to placebo * How much REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the study drugs less effective or could lead to side effects)

Phase 3
Recruiting

SEC Clinical Research (+4 Sites)

Clinical Trial Management

Regeneron Pharmaceuticals

Have you considered Inderal La clinical trials?

We made a collection of clinical trials featuring Inderal La, we think they might fit your search criteria.
Go to Trials